[Skip to Navigation]
April 1983

Praziquantel Therapy for Cysticercosis

Author Affiliations

Division of Neurology
Division of Infectious Diseases Department of Medicine Brown University Providence, RI 02908

Arch Neurol. 1983;40(4):257. doi:10.1001/archneur.1983.04050040087022

To the Editor.  —Both in their editorial entitled "Cysticercosis: An Old Scourge Revisited" (Archives 1982; 39:533) and in their article entitled "CNS Cysticercosis" (Archives 1982;39:540-544), Grisolia and Wiederholt commented that no specific medical therapy is available for neurocysticercosis. The accompanying article by McCormick et al (Archives 1982; 39:534-539) mentioned animal but not human studies using the acylated isoquinoline-pirazine compound praziquantel in the treatment of that condition, stating that "the ultimate role of this drug is yet to be defined." We wonder whether the authors of these three articles continue to believe there is no specific treatment for neurocysticercosis in light of the recently reported experience with praziquantel treatment of human diseases.1-4 In their latest study of 31 cases of neurocysticercosis, Botero and Castano4 reported a drop in mortality with praziquantel therapy, to 3.2% from an earlier range of 50% to 80%. A trial of praziquantel therapy may therefore be

Add or change institution